title: Recent developments in the treatment of inflammatory bowel disease.
abstract: Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases that have been treated with corticosteroids, 5-aminosalicates and thiopurines, but therapeutic options have been broadened with the arrival of anti-tumor necrosis factor antibodies. In this article we reviewed the current evidence-based approach to inflammatory bowel disease, the modifications that have been made to existing therapies and discussed new drugs that have shown success in clinical trials. The new drugs discussed here are those that disturb lymphocyte homing to the gut (natalizumab, vedolizumab and anti-mucosal addressin cellular adhesion molecule); one that blocks interleukin (IL)-12 as well as the IL-23/T helper 17 (Th17) axis (ustekinumab) and one that blocks the signaling of multiple cytokines (tofacitinib).
authors: Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors: Svend T
authors: ST
authors: Rietdijk
authors: Geert R
authors: GR
authors: D'Haens
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D019819:Budesonide / Q000008:administration & dosage; D000068582:Certolizumab Pegol; D055317:Evidence-Based Practice; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D019804:Mesalamine / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012294:Rifamycins / Q000627:therapeutic use; D000078262:Rifaximin; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D012294:Rifamycins; D011092:Polyethylene Glycols; D019804:Mesalamine; D019819:Budesonide; C529000:golimumab; D000069549:Ustekinumab; D000078262:Rifaximin; D000068582:Certolizumab Pegol